One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Personalised cancer vaccines and new regulatory struggles
doi : 10.1016/S1470-2045(25)00096-8
Volume 26, Issue 3, March 2025, Page 265
Destroy or delay: hormonal therapy in oligometastatic prostate cancer
Tailoring the treatment of premenopausal patients with breast cancer
Navigating the androgen receptor landscape in triple-negative breast cancer
Tailoring chemoimmunotherapy de-escalation in early-stage triple-negative breast cancer
UK's National Cancer Plan needs to be radical, accountable, and deliverable
Refining multimodal strategies for locally advanced NSCLC – Authors' reply
AI model using clinical images for genomic prediction and tailored treatment in patients with cancer
Revolutionising cancer treatment access in low-income and middle-income countries: a sustainable approach
Discussions on the future of cancer care at the World Economic Forum in 2025
More than three in five kidney cancer diagnoses in the UK are incidental
Law to extend free medical treatment for breast cancer in France
Call to prioritise access to essential cancer medicines in Latin America and the Caribbean
Sharp increase in patients waiting months for urgent cancer treatment
Global Platform for childhood cancer medicine access starts distributing drugs
Breast cancer survivor-led patient advocacy: the ICanServe experience from the Philippines
Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial
ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial
Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study
Activity and safety of atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (MARBLE): a multicentre, single-arm, phase 2 trial
Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 study
Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial
Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61–20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial
The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials
Comparative efficacy and safety of ablative therapies in the management of primary localised renal cell carcinoma: a systematic review and meta-analysis
Cancer surveillance in the Eastern Mediterranean region: a 10-year International Agency for Research on Cancer–WHO Regional Office for the Eastern Mediterranean collaboration
Active surveillance of cervical intraepithelial neoplasia grade 2: 2025 British Society of Colposcopy and Cervical Pathology and European Society of Gynaecologic Oncology consensus statement
Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation
Dose optimisation to improve access to effective cancer medicines
